CN1265799C - Composite of zinc containing compound and glutamines - Google Patents
Composite of zinc containing compound and glutamines Download PDFInfo
- Publication number
- CN1265799C CN1265799C CN 97109039 CN97109039A CN1265799C CN 1265799 C CN1265799 C CN 1265799C CN 97109039 CN97109039 CN 97109039 CN 97109039 A CN97109039 A CN 97109039A CN 1265799 C CN1265799 C CN 1265799C
- Authority
- CN
- China
- Prior art keywords
- zinc
- glutamines
- glutamine
- effect
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract description 28
- 239000011701 zinc Substances 0.000 title abstract description 28
- 229910052725 zinc Inorganic materials 0.000 title abstract description 28
- 235000004554 glutamine Nutrition 0.000 title abstract description 22
- 150000002309 glutamines Chemical class 0.000 title abstract 5
- 239000002131 composite material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims description 26
- 208000025865 Ulcer Diseases 0.000 claims description 10
- 231100000397 ulcer Toxicity 0.000 claims description 10
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 29
- 239000003814 drug Substances 0.000 abstract description 24
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 15
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 12
- 208000011906 peptic ulcer disease Diseases 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 11
- 210000002249 digestive system Anatomy 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000003405 preventing effect Effects 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 21
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 19
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 17
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 15
- 229960000905 indomethacin Drugs 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 7
- 230000001079 digestive effect Effects 0.000 description 6
- 206010048259 Zinc deficiency Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 235000003969 glutathione Nutrition 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 108010044940 alanylglutamine Proteins 0.000 description 4
- 229960002648 alanylglutamine Drugs 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 150000001447 alkali salts Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- -1 fluidizer Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LRGQZEKJTHEMOJ-UHFFFAOYSA-N propane-1,2,3-triol;zinc Chemical compound [Zn].OCC(O)CO LRGQZEKJTHEMOJ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DDKJKQVNNATMAD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;zinc Chemical compound [Zn].NCCCC[C@H](N)C(O)=O DDKJKQVNNATMAD-JEDNCBNOSA-N 0.000 description 1
- LQZFQLVBZRVDLJ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC(O)=O LQZFQLVBZRVDLJ-DKWTVANSSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- HUKGDBBEVQLTMY-KQBMADMWSA-N [Zn].N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O Chemical compound [Zn].N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O HUKGDBBEVQLTMY-KQBMADMWSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004582 acexamic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229940100888 zinc compound Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- GEVJDDLLVRRIOL-UHFFFAOYSA-L zinc;6-acetamidohexanoate Chemical compound [Zn+2].CC(=O)NCCCCCC([O-])=O.CC(=O)NCCCCCC([O-])=O GEVJDDLLVRRIOL-UHFFFAOYSA-L 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a composition comprising zinc compounds, and glutamines disclosed in formula (I) in a specification, which has the functions of immunological regulation, digestive system cytoprotection, and replenishment of zinc and/or glutamines to an organism. The composition is used as an effective component of a drug for preventing, controlling or treating peptic ulcer, peptic ulcer induced by a non-steroidal anti-inflammatory drug, harm of ethanol to a digestive system, relevant diseases caused by difficiency of zinc and/or glutamines, etc. Zinc compounds and glutamines are used as effective components which are made into a series of pharmacologically acceptable compositions.
Description
The present invention relates to contain the compositions of zinc compound and glutamy amine.Compositions is mainly formed by the acceptable zinc compound of pharmacy with suc as formula the glutamy amine shown in (I) or alkali metal, alkali salt or zinc compound.This compositions has immunoregulation effect, digestive system cytoprotection, cheats the effect of the additional zinc of body and/or the effect of additional glutamine.This compositions is as the active ingredient of prevention, control or treatment digestive ulcer medicament; Bring out the active ingredient of digestive ulcer medicament as prevention, control or treatment NSAID (non-steroidal anti-inflammatory drug); Prevention, control or treatment ethanol are to the active ingredient of digestion system damage medicine; Cause the active ingredient of diseases related medicine as prevention, control or treatment body zinc deficiency; Cause the active ingredient of diseases related medicine as prevention, control or treatment body glutamine shortage.Zinc compound and glutamy amine and pharmaceutic adjuvant, perhaps other medicines are made a series of pharmacy acceptable composition.
The glutamine compounds is characterized in that in the formula (I):
Formula (I)
R
1Be H, R
2It when being H L-glutaminate;
R
1Be-COCH
3, R
2When being H acetylglutamide [N-acetyl-L-glutamine];
R
1Be-COCH
2CH
2NH
2, R
2When being H alanyl glutamine [N-alanyl-L-glutamine];
R
1Be H, R
2Be
The time be to be glutathion [γ-L-glutamy-L-cysteinyl-glycine] or their pharmaceutically acceptable alkali metal, alkali salt or zinc compound.
Zinc is biological element, belong to essential trace element, content is only second to ferrum and occupies second in human body, has very important Nutrition, just confirm that in 1934 zinc is human indispensable biological element, known zinc is present in 200 plurality of enzymes, zinc and nucleic acid and protein metabolism are closely related, in the retina location, keep vision and taste function, aspects such as the normal growth of skeleton all are essential, particularly the g and D to the child has important function, improves the immunocompetence of body, promotes wound healing, and can prevent or treat peptic ulcer, the prevention carbon tetrachloride, ethanol, hepatic injury due to alkylating agent and the cadmium.Zinc deficiency can cause the immune organ dysplasia, and influences the natural defending system of humoral immunization, cellular immunization, complement system and body, by replenishing an amount of zinc, body's immunological function is recovered.Zinc compound has been used for sicklemia, rheumatoid arthritis, at wound healing, zinc deficiency, viral influenza, infantile diarrhea, hepatic disease and the gastric ulcer of operations such as acute tissue injury, burn, surgery, promote body's immunological function to recover, certain therapeutical effect is arranged.
Just found that zinc compound had certain therapeutical effect to peptic ulcer in 72 years clinically, found that zinc compound had prevention and therapeutical effect to experimental peptic ulcer model in 1976, zinc compound has human body immunity improving ability and digestive system cytoprotection; Has the biological cell membrane stabilizing action, prevent mast cell degranulation, suppress to discharge the effect of histamine, zinc is by the activity of metal sulfydryl albumen and glutathion, has the effect of removing free radical, keep gastrointestinal tract mucous epithelial cell integrity, prevent NSAID (non-steroidal anti-inflammatory drug) as: aspirin, indomethacin etc. causes the destruction and the PGE of gastric mucosal barrier
2With the protective effect that mucus reduces, quicken the division and the propagation of cell, the reparation of damage location there is the healing of promotion effect.Zinc compound has the stomach of inhibition H
+, K
+The effect of-ATP enzyme, zinc compound not only suppress urease, suppress the growth of campylobacter pyloridis, and clinical treatment has also been proved conclusively zinc compound campylobacter pyloridis is had good killing action.There have been four kinds of organic zinc compound class medicines [zinc glycyrrhetate, Zinc Acexamate, glycerin zinc and alanylhistidine zinc] to be used for the treatment of peptic ulcer.
In a word, zinc compound is when the treatment peptic ulcer, though have cytoprotection, zinc ion all is to work indirectly, can not participate in histiocytic reparation and formation directly, can not provide to repair required energy and nutrient substance.Therefore certain defective that the existing zinc compound class medicine that is used for the treatment of peptic ulcer exists on treatment mechanism.
Purpose of the present invention is to improve at above-mentioned the deficiencies in the prior art, but proposes a kind of compositions of hyoscine, and compositions mainly is made up of zinc compound and glutamy amine, i.e. acceptable zinc compound of pharmacy and the acceptable salt of glutamy amine pharmacy.
Reported that glutamine had the effect of the irritability gastric mucosa injury of prevention rat in 68 years, nearest result of study has changed the view of for a long time paddy ammonia amine acyl physiological action importance being underestimated, paddy ammonia amine acyl is main nutrition of digestive system and energy source, glutamine provides energy for gastrointestinal tract mucous epithelial cell, help to keep gastrointestinal organ's metabolism, to protecting and safeguarding that the structure and the function of the organ of digestive system have important effect, paddy ammonia amine acyl is aminoacid, proteinic synthetic provide nitrogenous source and energy; Participate in DNA, RNA precursor--synthesizing of purine and pyrimidine, improve DNA and the protein content and the mucosal thickness of gastrointestinal mucosa, promote the reparation of damage location; For immunocyte division and immunoglobulin,exocrine provide nitrogenous source and energy, raising gastrointestinal tract immunologic function, and be considered to immunomodulator; Can promote cell to upgrade and regeneration, protect the gastrointestinal mucosa barrier, keep the integrity of mucosa form and structure; Participate in the synthetic of the sweet smooth peptide of paddy, resist the biomembranous infringement of radical pair indirectly.Promote brain development in addition, improve intelligence, prevention and treatment carbon tetrachloride, ethanol or cadmium the effect of hepatic injury, the certain effect of performance in acute tissue injury, burn, surgical operation.The glutamy amine be used for separately peptic ulcer and or the NSAID (non-steroidal anti-inflammatory drug) treatment of peptic ulcer effect of bringing out undesirable.
In order to realize purpose of the present invention, one of active ingredient zinc compound is meant in this compositions: the acceptable zinc compounds of pharmacy such as zinc acetate, zinc chloride, zinc sulfate, zinc phosphate, [alkali formula] zinc carbonate, zinc oxide, zinc hydroxide, Zinc acelylsalicylate, indomethacin zinc, zinc gluconate, structure rafter acid zinc, zinc lysine, Aspartic acid zinc, zinc glycyrrhetate, glycerin zinc, alanylhistidine zinc, acetylamino caproic acid zinc, zinc P-acetlaminoacetate, zinc stearate or zinc propionate.
In order to realize purpose of the present invention, one of active ingredient glutamy amine is meant in this compositions: L-glutaminate, acetylglutamide [N-acetyl-L-glutamine], alanyl glutamine [N-alanyl-L-glutamine], glutathion [γ-L-glutamy-L-cysteinyl-glycine] or alkali metal, alkali salt or zinc compound.
Zinc compound and glutamine based composition have immunoregulation effect, digestive system cytoprotection, replenish a series of physiologically actives such as effect of zinc and/or additional glutamine to body.
The dehydrated alcohol experiment shows: compositions has the digestive system cytoprotection, has prevention or the treatment ethanol detrimental effect to digestive system, the effect of prevention and treatment peptic ulcer, and prevention and treatment ethanol are to the immanoprotection action of the infringement of mucosa.Indomethacin be in the non-steroidal anti-inflammatory medicine to the strongest medicine of mucosal injury effect, indomethacin experiment shows: compositions has the effect that prevention or treatment NSAID (non-steroidal anti-inflammatory drug) are brought out peptic ulcer, and the active ingredient of compositions has collaborative pharmacological action.
The purposes of zinc compound and glutamine based composition is: as the active ingredient of prevention, control or treatment digestive ulcer medicament; Bring out the active ingredient of digestive ulcer medicament as prevention, control or treatment NSAID (non-steroidal anti-inflammatory drug); As the active ingredient of prevention, control or treatment ethanol to digestion system damage medicine; Cause the active ingredient of diseases related medicine as prevention, control or treatment body zinc deficiency and/or lack and cause the active ingredient of diseases related medicine as prevention, control or treatment body glutamine.
Compare with zinc compound or independent use of glutamy amine; at immunoregulation effect; the digestive system cytoprotection; replenish aspects such as zinc and/or additional glutamine effect to body; the pharmacological action of zinc compound and glutamine based composition is more perfect; more comprehensive; more reasonable; the indirect cytoprotection that promptly has zinc ion; the effect that nutrient substance such as ammonia source and energy are provided for gastrointestinal tract of glutamine is also arranged; and participate in biosynthetic direct cytoprotection; compare with single active ingredient; the active ingredient of compositions has collaborative pharmacological action, and compositions has outstanding substantive distinguishing features and significant technological progress.
In order to realize purpose of the present invention, with zinc compound and glutamy amine, handle according to the acceptable method of pharmaceutics, be prepared into a series of pharmaceutically acceptable preparations.
The type of service of zinc compound and glutamine based composition is, zinc compound and glutamy amine do not add or add as: excipient, binding agent, disintegrating agent, fluidizer, lubricant, coloring agent, correctives, sweeting agent, stabilizing agent, controlled release agent, coating materials, pharmaceutic adjuvants such as isotonic agent, make per os or non-per os as: for oral, intramuscular injection, subcutaneous injection, intravenous injection, rectum, the solid that vagina and skin etc. use, the compositions of form of medication such as semi-solid and liquid is as tablet, coated tablet, coated tablet, chewable tablet, buccal tablet, hard capsule, soft capsule, transfer release formulation, pill, granule, pulvis subtilis, powder, solution, oral liquid, suspension, Emulsion, injection [liquid], aseptic [lyophilizing] powder pin, oil [water] dissolubility substrate rectal suppository, oil [water] dissolubility substrate vaginal suppository, membrane, oil [water] dissolubility ointment, various pharmacy acceptable forms such as plaster.
The main compositions of being made up of zinc compound and glutamy amine also can contain glucose, fructose, galactose, leucine, isoleucine, lysine, methionine, acetylmethionine, phenylalanine, threonine, tryptophan, valine, citrulline, ornithine, acetyl hydroxyproline, proline, glycine, alanine, histidine or N-alanyl-L-histidine or alkali metal, alkali salt or zinc compound, vitamin E, misoprostol, H as active ingredient
2Medicines such as receptor antagonist, proton pump inhibitor, antacid, antipyretic analgesic, NSAID (non-steroidal anti-inflammatory drug) or golden preparation and pharmaceutic adjuvant etc., make per os or non-per os as the compositions that can accept form of medication for the pharmacy such as solid, semisolid and liquid of uses such as oral, intramuscular injection, subcutaneous injection, quiet injection arteries and veins, rectum, vagina and skin, have immunoregulation effect, digestive system cytoprotection, replenish the zinc effect and replenish the glutamine effect, as the active ingredient of prevention, control or treatment digestive ulcer medicament to body to body; Bring out the active ingredient of digestive ulcer medicament as prevention, control or treatment NSAID (non-steroidal anti-inflammatory drug); Prevention, control or treatment ethanol are to the active ingredient of digestion system damage medicine; Cause the active ingredient of diseases related medicine and/or prevention, control or treatment body glutamine to lack as prevention, control or treatment body zinc deficiency and cause the active ingredient of diseases related medicine.
The use amount of this compositions effective ingredient every day is respectively: oral zinc compound is that 1mg～1000mg[is with the zinc cubage] and the glutamy amine be 1mg～90g[with corresponding glutamy amine content: glutamine, acetylglutamide, alanyl glutamine or glutathion are effective dose or total]; Non-per os use zinc compound as 1mg～3000mg[with the zinc cubage] and glutamine as 1mg～90g[with corresponding glutamy amine content: glutamine, acetylglutamide, alanyl glutamine or glutathion are effective dose or total], according to the concrete conditions such as symptom degree of age, body weight, disease type, disease, divide for several times every day and use.
This compositions does not have significant side effects to health, meets social need, can be applied to commercial production.
Below in conjunction with embodiment the pharmacological effect of inventive compositions is further described:
Embodiment 1:
Influence to indomethacin and alcohol-induced gastric mucosa injury:
(Gastroenterology 1979 to press the method for Robert etc.; 77:433), compositions with acetylglutamide (300mg/kg/d) and zinc P-acetlaminoacetate (100mg/kg/d) is given rat oral gavage three days, administration is preceding 30 minutes the last time, indomethacin with 30mg/kg dosage is irritated stomach, irritate the dehydrated alcohol of stomach 1ml after 3 hours, after 1 hour, locate rat, measure the ulcer length that is caused.
(Gastroenterology 1979 to press the method for Robert etc.; 77:433), compositions with acetylglutamide (300mg/kg/d), zinc P-acetlaminoacetate (100mg/kg/d), acetylglutamide (300mgmg/kg/d) and zinc P-acetlaminoacetate (100mg/kg/d) is given rat oral gavage three days, the dehydrated alcohol of stomach 1ml is irritated in administration after 3 hours the last time, after 1 hour, locate rat, measure the ulcer length that is caused.
Table zinc P-acetlaminoacetate and acetylglutamide are to indomethacin and alcohol-induced gastric mucosa
The influence [ulcer length (mm)] of damage
| Dehydrated alcohol | Dehydrated alcohol+indomethacin | ||||
| Blank group | Compositions | Blank group | Zinc P-acetlaminoacetate | Acetylglutamide | Compositions |
| 73.1±17.5 | 16.3±4.4 | 120.9±18.2 | 51.3±14.9 | 39.4±7.9 | 26.7±5.7 |
Claims (1)
1. the pharmacy acceptable composition with anti-digestive system and ulcer effect is characterized in that containing zinc compound and glutamine compounds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109039 CN1265799C (en) | 1997-03-17 | 1997-03-17 | Composite of zinc containing compound and glutamines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109039 CN1265799C (en) | 1997-03-17 | 1997-03-17 | Composite of zinc containing compound and glutamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1166320A CN1166320A (en) | 1997-12-03 |
| CN1265799C true CN1265799C (en) | 2006-07-26 |
Family
ID=5170863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97109039 Expired - Fee Related CN1265799C (en) | 1997-03-17 | 1997-03-17 | Composite of zinc containing compound and glutamines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1265799C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051742A1 (en) | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
| CN102973541A (en) * | 2011-09-02 | 2013-03-20 | 徐州医学院 | Use of L-citrulline in preparation of anti-gastric ulcer drugs |
| CN103750344B (en) * | 2014-01-25 | 2015-11-04 | 北京凯因科技股份有限公司 | A kind of yeast glutathione nutritional preparation |
| KR102094182B1 (en) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | water-soluble polyglutamic acid complex composition containing zinc |
-
1997
- 1997-03-17 CN CN 97109039 patent/CN1265799C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1166320A (en) | 1997-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goyal et al. | Asparagus racemosus-an update | |
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| WO2016062283A1 (en) | Applications of anti-inflammatory medicament in preparing cancer-inhibiting pharmaceutical composition | |
| CN1302771C (en) | 2-(4-isobutylphenyl) propionic acid medicinal composition | |
| JPS6245535A (en) | Acylcarnitines as absorption enhancer for supplying drug through mucosa of nose, mouth, tongue and vagina | |
| EP0980245A1 (en) | Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction | |
| CN1265799C (en) | Composite of zinc containing compound and glutamines | |
| AU2003204391A1 (en) | Composition and its therapeutic use | |
| CN1135178A (en) | Treatment of uterine contractility disorders with nitric oxide synthase substrates and/or donors, or nitric oxide inhibitors | |
| US20200170990A1 (en) | Method for treating schnitzler's syndrome | |
| WO2024078507A1 (en) | Use of ergosterol in preparation of drug for preventing and treating gastric ulcers | |
| US5294440A (en) | Composition for treatment of cold sores | |
| CN1076195C (en) | Composition containing zinc compound and p-acetaminophenyl acetic acid | |
| RU2218172C1 (en) | Method for treating the cases of psoriasis | |
| JP4370054B2 (en) | Preventive and therapeutic agent for intestinal mucosal injury | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| WO2019128511A1 (en) | Use of pien tze huang or preparation thereof in preparing drug for treating postherpetic neuralgia | |
| US4537908A (en) | Herpes II treatment | |
| Saisakphong et al. | Effect of Vitamin C on postoperative pain after dental implant surgery | |
| Capurso et al. | Cimetidine, 800 mg at night versus 400 mg twice daily, in the treatment of duodenal ulcer | |
| BRPI0902144A2 (en) | process for preparing a solid oral administration pharmaceutical composition containing the active ingredients glycosamine and meloxicam and use of the association between glycosamine and meloxicam | |
| US6897239B1 (en) | Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women | |
| CN1378451A (en) | Pharmaceuticla ocmpositions for treating psoriasis | |
| RU2294204C1 (en) | Method for treatment of stomach and duodenum ulcerous disease | |
| US20100203146A1 (en) | Intermittent dosing strategy for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Xia Xiaolin Document name: patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Xia Xiaolin Document name: payment instructions |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |